A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Rasmus T. Hoeg; Julian Davis; Brian A. Jonas; Joseph Tuscano; Aaron Rosenberg; Mehrdad Abedi

doi:10.1016/j.clml.2020.02.006

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Rasmus T. Hoeg, Julian Davis, Brian A. Jonas, Joseph Tuscano, Aaron Rosenberg, Mehrdad Abedi

Hematology and Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.

Original language	English (US)
Journal	Clinical Lymphoma, Myeloma and Leukemia
DOIs	https://doi.org/10.1016/j.clml.2020.02.006
State	Accepted/In press - Jan 1 2020

Keywords

Hodgkin lymphoma
Multiple myeloma
Non-Hodgkin lymphoma

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.clml.2020.02.006

Fingerprint Dive into the research topics of 'A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies'. Together they form a unique fingerprint.

Cite this

@article{d45616cee28947739b52641bbef5d3da,

title = "A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies",

abstract = "This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.",

keywords = "Hodgkin lymphoma, Multiple myeloma, Non-Hodgkin lymphoma",

author = "Hoeg, {Rasmus T.} and Julian Davis and Jonas, {Brian A.} and Joseph Tuscano and Aaron Rosenberg and Mehrdad Abedi",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/j.clml.2020.02.006",

language = "English (US)",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2669",

publisher = "Cancer Media Group",

}

TY - JOUR

T1 - A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

AU - Hoeg, Rasmus T.

AU - Davis, Julian

AU - Jonas, Brian A.

AU - Tuscano, Joseph

AU - Rosenberg, Aaron

AU - Abedi, Mehrdad

PY - 2020/1/1

Y1 - 2020/1/1

N2 - This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.

AB - This is the first study to examine the combination of everolimus and bendamustine in the treatment of lymphoid hematologic malignancies. Eighteen patients with relapsed/refractory lymphoma and multiple myeloma were treated. Toxicities were mainly hematologic. Response rates varied by malignancy from 20% to 100%.

KW - Hodgkin lymphoma

KW - Multiple myeloma

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85081564021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081564021&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.02.006

DO - 10.1016/j.clml.2020.02.006

M3 - Article

C2 - 32171691

AN - SCOPUS:85081564021

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -

A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this